AGN208397
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AGN208397, covering 2014-04-29 to 2014-04-29. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO) [Phase 1, Phase 2]